PPAR-γ agonists:: therapeutic role in diabetes, inflammation and cancer

被引：342

作者：

Murphy, GJ

Holder, JC

机构：

[1] SmithKline Beecham Pharmaceut, Dept Vasc Biol, MFSPIN, Harlow CM19 5AD, Essex, England

[2] SmithKline Beecham Pharmaceut, Mol Toxicol Grp, MFSPIN, Harlow CM19 5AD, Essex, England

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2000年 / 21卷 / 12期

关键词：

D O I：

10.1016/S0165-6147(00)01559-5

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The recent development of a novel class of insulin-sensitizing drugs, the thiazolidinediones (TZDs), represents a significant advance in antidiabetic therapy. One key mechanism by which these drugs exert their effects is by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma), a member of the nuclear receptor family. Evidence supporting this mechanism of action of the TZDs will be reviewed in this article. Recent data suggests that PPAR-gamma agonists might also have therapeutic potential in the treatment of inflammatory diseases and certain cancers.

引用

收藏

页码：469 / 474

页数：6

相关论文

共 59 条

[31] Effect of troglitazone on body fat distribution in type 2 diabetic patients [J].

Mori, Y ;

Murakawa, Y ;

Okada, K ;

Horikoshi, H ;

Yokoyama, J ;

Tajima, N ;

Ikeda, Y .

DIABETES CARE, 1999, 22 (06) :908-912

[32] Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ [J].

Nagy, L ;

Tontonoz, P ;

Alvarez, JGA ;

Chen, HW ;

Evans, RM .

CELL, 1998, 93 (02) :229-240

[33] Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ [J].

Nolte, RT ;

Wisely, GB ;

Westin, S ;

Cobb, JE ;

Lambert, MH ;

Kurokawa, R ;

Rosenfeld, MG ;

Willson, TM ;

Glass, CK ;

Milburn, MV .

NATURE, 1998, 395 (6698) :137-143

[34] NOVEL SEQUENCE DETERMINANTS IN PEROXISOME PROLIFERATOR SIGNALING [J].

PALMER, CNA ;

HSU, MH ;

GRIFFIN, KJ ;

JOHNSON, EF .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (27) :16114-16121

[35] Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-γ [J].

Park, KS ;

Ciaraldi, TP ;

Lindgren, K ;

Abrams-Carter, L ;

Mudaliar, S ;

Nikoulina, SE ;

Tufari, SR ;

Veerkamp, JH ;

Vidal-Puig, A ;

Henry, R .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (08) :2830-2835

[36] PPAR-gamma gene expression is elevated in skeletal muscle of obese and Type II diabetic subjects [J].

Park, KS ;

Ciaraldi, TP ;

AbramsCarter, L ;

Mudaliar, S ;

Nikoulina, SE ;

Henry, RR .

DIABETES, 1997, 46 (07) :1230-1234

[37] Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling [J].

Peraldi, P ;

Xu, M ;

Spiegelman, BM .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (07) :1863-1869

[38] Treatment of psoriasis with troglitazone therapy [J].

Pershadsingh, HA ;

Sproul, JA ;

Benjamin, E ;

Finnegan, J ;

Amin, NM .

ARCHIVES OF DERMATOLOGY, 1998, 134 (10) :1304-1305

[39] Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein [J].

Ricote, M ;

Huang, J ;

Fajas, L ;

Li, A ;

Welch, J ;

Najib, J ;

Witztum, JL ;

Auwerx, J ;

Palinski, W ;

Glass, CK .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (13) :7614-7619

[40] The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation [J].

Ricote, M ;

Li, AC ;

Willson, TM ;

Kelly, CJ ;

Glass, CK .

NATURE, 1998, 391 (6662) :79-82

← 1 2 3 4 5 6 →